Pfizer details Phase 2 data for its infant pneumococcal vaccine candidate
In the study, a four-dose series elicited immune responses against all 25 serotypes.
GetSignal Pfizer Inc. PFE
Pfizer announced on October 24, 2026, detailed results from a Phase 2 study of its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. The data were presented at IDWeek 2026.
Safety and tolerability were comparable to four doses of PREVNAR 20, a 20-valent pneumococcal conjugate vaccine.
Key facts
- Candidate
- PF-07872412 (25vPnC)
- Study
- Phase 2, NCT06524414
- Dosing
- Four-dose series in infants
- Comparator
- Four doses of PREVNAR 20
Source: The company's release on Business Wire, October 24, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
